AngioDynamics, Inc. (ANGO) is gearing up to report its second-quarter earnings results before the opening bell on Tuesday, January 6, 2026. If you're tracking this medical device maker, here's what Wall Street's most accurate analysts are expecting.
The consensus calls for the Latham, New York-based company to post a quarterly loss of 10 cents per share. That's wider than the 4-cent loss the company reported in the same quarter last year, which might sound concerning at first glance. But there's more to the story when you look at the revenue picture.
Analysts are projecting quarterly revenue of $76.43 million, up from $72.84 million in the year-ago period. That's solid top-line growth of nearly 5%, suggesting the business is expanding even if profitability remains elusive for now.
Worth noting: back on October 2, AngioDynamics actually raised its full-year FY26 adjusted EPS guidance, which typically signals management confidence in the business trajectory. That forward-looking optimism provides some context for the current quarter's expectations.
The stock closed Friday at $12.87, down 1.8% for the session. That puts shares well below where the most bullish analysts think they should be trading.
What Top Analysts Are Saying
Let's look at recent ratings from analysts with proven track records of accuracy on AngioDynamics.
Canaccord Genuity analyst William Plovanic maintained his Buy rating on October 3, 2025, and actually raised his price target from $17 to $18. That represents about 40% upside from current levels. Plovanic has an accuracy rate of 62% on his stock calls.
HC Wainwright & Co. analyst Yi Chen also maintains a Buy rating with a $16 price target, issued on July 16, 2025. Chen brings an even stronger track record with a 66% accuracy rate.
Both analysts clearly see value at current prices, even with the expected quarterly loss approaching. The real question for investors is whether the revenue growth and improved full-year guidance will be enough to justify their optimism when the company reports next week.